221 related articles for article (PubMed ID: 18637895)
1. Brunsting-Perry cicatricial pemphigoid associated with autoantibodies to the C-terminal domain of BP180.
Daito J; Katoh N; Asai J; Ueda E; Takenaka H; Ishii N; Hashimoto T; Kishimoto S
Br J Dermatol; 2008 Sep; 159(4):984-6. PubMed ID: 18637895
[No Abstract] [Full Text] [Related]
2. Brunsting-Perry-type cicatricial pemphigoid with IgG autoantibodies to LAD-1.
García-Martín P; Fraga J; Hashimoto T; García-Diez A
Br J Dermatol; 2014 Mar; 170(3):743-5. PubMed ID: 24124894
[No Abstract] [Full Text] [Related]
3. Mucous membrane pemphigoid with immunoglobulin G autoantibodies against full-length and 120-kDa ectodomain of BP180.
Choi Y; Lee SE; Fukuda S; Hashimoto T; Kim SC
J Dermatol; 2011 Feb; 38(2):169-72. PubMed ID: 21269314
[TBL] [Abstract][Full Text] [Related]
4. Pure ocular mucous membrane pemphigoid reactive with both β4 integrin and the BP180 C-terminal domain.
Solano-López G; Concha-Garzón MJ; Sánchez-Pérez J; Hirako Y; Li X; Ishii N; Hashimoto T; Daudén E
Br J Dermatol; 2015 Feb; 172(2):542-4. PubMed ID: 25059542
[No Abstract] [Full Text] [Related]
5. Detection of mucous membrane pemphigoid autoantibodies by full-length BP180 enzyme-linked immunosorbent assay.
Izumi K; Nishie W; Mai Y; Ujiie H; Iwata H; Natsuga K; Shimizu H
J Dermatol Sci; 2017 Nov; 88(2):247-248. PubMed ID: 28736219
[No Abstract] [Full Text] [Related]
6. Cicatricial pemphigoid sera specifically react with the most C-terminal portion of BP180.
Lee JB; Liu Y; Hashimoto T
J Dermatol Sci; 2003 Jun; 32(1):59-64. PubMed ID: 12788530
[TBL] [Abstract][Full Text] [Related]
7. Acute blistering disease presenting IgG autoantibodies against NC16A and COOH-terminal domains of BP180 and laminin-332, with characteristic distribution of eruptions.
Kurashige Y; Minemura T; Nagatani T; Koga H; Hashimoto T
Eur J Dermatol; 2013; 23(1):109-10. PubMed ID: 23306276
[No Abstract] [Full Text] [Related]
8. Study of original B cells producing pathogenic IgG and IgA autoantibodies in anti-BP180-type mucous membrane pemphigoid.
Hayashi D; Hashimoto T; Mine M; Ishii N; Hashimoto K; Tsuchisaka A; Tsuruta D
Arch Dermatol Res; 2024 May; 316(5):169. PubMed ID: 38734797
[No Abstract] [Full Text] [Related]
9. Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain.
Balding SD; Prost C; Diaz LA; Bernard P; Bedane C; Aberdam D; Giudice GJ
J Invest Dermatol; 1996 Jan; 106(1):141-6. PubMed ID: 8592065
[TBL] [Abstract][Full Text] [Related]
10. A case of bullous pemphigoid associated with autoantibodies targeting antigenic sites other than the NC16a domain of BP180.
Shinojima Y; Ochiai T; Kawamura A; Arakawa H; Fukuda K; Hashimoto T
Clin Exp Dermatol; 2005 Sep; 30(5):503-5. PubMed ID: 16045678
[TBL] [Abstract][Full Text] [Related]
11. Anti-BP180-type oral mucous membrane pemphigoid reactive to both NC16a and C-terminal domains.
Uchiyama M; Mitsuhashi Y; Tsuboi R; Ishii N; Hayakawa T; Yasukochi A; Hashimoto T
Indian J Dermatol Venereol Leprol; 2015; 81(6):637-9. PubMed ID: 26515855
[No Abstract] [Full Text] [Related]
12. Mucous membrane pemphigoid with generalized blisters: IgA and IgG autoantibodies target both laminin-332 and type XVII collagen.
Hayashi I; Shinkuma S; Shimizu S; Natsuga K; Ujiie H; Yasui C; Tsuchiya K; Nishie W; Shimizu H
Br J Dermatol; 2012 May; 166(5):1116-20. PubMed ID: 22182184
[TBL] [Abstract][Full Text] [Related]
13. A case of anti-BP180 type mucous membrane pemphigoid treated with intravenous immunoglobulin.
Aoki N; Nakajima K; Shiga T; Koga H; Hashimoto T; Sano S
J Dermatol; 2014 Jun; 41(6):557-9. PubMed ID: 24909219
[No Abstract] [Full Text] [Related]
14. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid.
Di Zenzo G; Thoma-Uszynski S; Fontao L; Calabresi V; Hofmann SC; Hellmark T; Sebbag N; Pedicelli C; Sera F; Lacour JP; Wieslander J; Bruckner-Tuderman L; Borradori L; Zambruno G; Hertl M
Clin Immunol; 2008 Sep; 128(3):415-26. PubMed ID: 18571472
[TBL] [Abstract][Full Text] [Related]
15. Brunsting-Perry type pemphigoid with IgG autoantibodies to laminin-332, BP230 and desmoplakins I/II.
Fukuda S; Tsuruta D; Uchiyama M; Mitsuhashi Y; Kobayashi H; Ishikawa T; Ohyama B; Ishii N; Hamada T; Dainichi T; Karashima T; Nakama T; Yasumoto S; Hashimoto T
Br J Dermatol; 2011 Aug; 165(2):433-5. PubMed ID: 21457206
[No Abstract] [Full Text] [Related]
16. Brunsting-Perry type localized bullous pemphigoid, possibly induced by furosemide administration and sun exposure.
TAKEICHI S; KUBO Y; ARASE S; HASHIMOTO T; ANSAI S
Eur J Dermatol; 2009; 19(5):500-3. PubMed ID: 19502152
[TBL] [Abstract][Full Text] [Related]
17. Indirect immunofluorescence in mucous membrane pemphigoid: which substrate should be used?
Maglie R; Borgi A; Caproni M; Antiga E
Br J Dermatol; 2019 May; 180(5):1266-1267. PubMed ID: 30693475
[No Abstract] [Full Text] [Related]
18. [Localized cicatricial bullous pemphigoid of the Brunsting-Perry type].
Kurzhals G; Maciejewski W; Agathos M; Meurer M; Mily H; Breit R
Hautarzt; 1993 Feb; 44(2):110-3. PubMed ID: 8449691
[TBL] [Abstract][Full Text] [Related]
19. Cicatrising conjunctivitis with anti-basement membrane autoantibodies in ectodermal dysplasia.
Saw VP; Dart JK; Sitaru C; Zillikens D
Br J Ophthalmol; 2008 Oct; 92(10):1403-10. PubMed ID: 18815422
[TBL] [Abstract][Full Text] [Related]
20. Autoantibodies against type XVII collagen C-terminal domain in a patient with bullous pemphigoid associated with psoriasis vulgaris.
Inokuma D; Kodama K; Natsuga K; Kasai M; Abe M; Nishie W; Abe R; Hashimoto T; Shimizu H
Br J Dermatol; 2009 Feb; 160(2):451-4. PubMed ID: 19077079
[No Abstract] [Full Text] [Related]
[Next] [New Search]
